Advanced NSCLC
Conditions
Brief summary
This is a phase II, Single-arm,Open-label Study evaluating the safety and efficacy of CT053PTSA in Advanced Solid Tumors With MET Exon 14 Skipping Mutations
Detailed description
This study is being carried out in two parts, part 1 and part 2. Part 1:Observation phase of dose tolerance: Objective To observe the tolerability and safety of 60 mg CT053PTSA in advanced NSCLC patients with Metex14 skipping mutation, and to determine the recommended dose (RED) in the dose expansion phase。 Part 2: This is the expansion part and will continue to evaluate the safety and efficacy of CT053PTSA at the dose of RED in advanced NSCLC patients with Metex14 skipping mutation.
Interventions
DRUGCT053PTSA
CT053PTSA will be administered orally once a day
Sponsors
Sunshine Lake Pharma Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age:18-75 years, male or female. * Histologically or cytologically confirmed IIIB-IV- Advanced NSCLC * There was a Metex 14 skipping mutation in plasma and / or tissue * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 \~2 * Life expectancy of greater than 12 weeks. * Evaluable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 * Adequate organ function. * Contraception, fertility and not lactating female subjects: screening blood pregnancy test must be negative * Voluntarily join the study and sign informed consent ad has good compliance.
Exclusion criteria
* EGFR or ALK or ROS1 gene mutation was positive * Anthracycline, nitrosourea, and mitomycin within 6 weeks; traditional Chinese medicine for anti-tumor within 2 weeks;other anti-tumor therapies within 4 weeks, Previously or currently participating in other clinical trials within 4 week, Prior therapies with c-MET targeted drugs; Had received vaccine within 4 weeks prior to study treatment or had a plan to receive vaccine during the trial. * Not recovered from adverse events due to a previously administered agent. * Symptomatic, untreated or unstable central nervous system metastases/ spinal cord compression, cancerous meningitis, or meningitis. * Patients with other malignant tumors except NSCLC within 5 years before the first use of drugs do not include those with negligible risk of metastasis or death (such as expected 5-year OS \> 90%) and expected to be cured after treatment, or any other tumors that have been cured (no evidence of recurrence within 5 years) * There are prescribed cardiovascular and cerebrovascular risk factors * Patients with evidence of bleeding tendency, or melena or hematemesis within 2 months; or visceral bleeding that may occur considered by investigator * History of thyroid dysfunction, and the thyroid function cannot be maintained at the normal range with drugs. * There are uncontrollable and active infections * Uncontrollable massive pleural / ascites or pericardial effusion * Clinically significant gastrointestinal abnormalities may affect the drug intake, transport or absorption (such as inability to swallow, chronic diarrhea, intestinal obstruction, etc.), or total gastrectomy subjects; * a history of psychotropic drug abuse and can not quit or have mental disorders * Any other reason the investigator considers the patient is not suitable to participate in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recommended Extended Dose | Cycle 1Day 1 to Cycle 1 Day 28±3 | Recommended dose for expansion phase |
| Objective response rate | up to 4 years | Objective response rate (ORR) is defined as the percentage of the participants in the analysis population who have a confirmed complete response (CR) or partial response (PR) based on RECIST 1.1 by investigators |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of response | up to 4 years | Defined as the time from the earliest date of qualifying response until earliest date of disease progression, per RECIST v1.1, or death from any cause, whichever comes first. Includes participants with complete response or partial response |
| Progression-free survival | up to 4 years | defined as the time from date of randomization until the earliest date of disease progression, as determined by independent central review of objective radiographic disease assessments per RECIST 1.1, or death from any cause, whichever comes first. |
| Overall survival | up to 4 years | Defined as time from date of randomization to date of death due to any cause. OS was calculated using product-limit (Kaplan-Meier) method for censored data. |
| Disease Control Rate | up to 4 years | proportion of patients with best overall response of CR, PR or stable disease (SD) |
| Adverse events related to CT053 | up to 4 years | description, timing, grade (Common Terminology Criteria for Adverse Events Version 5.0 \[CTCAE v5.0\]), severity, seriousness, and relatedness |
Contacts
PRINCIPAL_INVESTIGATORLi Zhang, MD
Sun Yat-sen University
Outcome results
None listed